Clinical Trial Update: The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk [Phase 3]

View source ↗

Summary

Phase 3 trial comparing 4R-CHOP+4R to 6R-CHOP+2R in newly diagnosed diffuse large B-cell lymphoma patients; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• 4R-CHOP+4R
• 6R-CHOP+2R

Snippet

Sponsor: Ruijin Hospital | Conditions: Diffuse Large B Cell Lymphoma | Phase 3 | Status: UNKNOWN